OSELTAMIVIR Drug Patent Profile
✉ Email this page to a colleague
When do Oseltamivir patents expire, and when can generic versions of Oseltamivir launch?
Oseltamivir is a drug marketed by Accord Hlthcare, Alembic, Amneal Pharms, Beijing Jialin, Cediprof Inc, Epic Pharma Llc, Hetero Labs Ltd Iii, Invagen Pharms, Laurus, Lupin, Macleods Pharms Ltd, MSN, Natco, Rising, Shandong, Strides Pharma, Sunshine, Upsher Smith Labs, Zhejiang Poly Pharm, Zydus Pharms, Ajanta Pharma Ltd, Alvogen, Amneal Pharms Ny, Aurobindo Pharma Ltd, Hetero Labs Ltd V, Jubilant Generics, Leading, Pharmobedient, and Teva Pharms Usa. and is included in thirty-six NDAs.
The generic ingredient in OSELTAMIVIR is oseltamivir phosphate. There are eight drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the oseltamivir phosphate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Oseltamivir
A generic version of OSELTAMIVIR was approved as oseltamivir phosphate by NATCO on August 3rd, 2016.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for OSELTAMIVIR?
- What are the global sales for OSELTAMIVIR?
- What is Average Wholesale Price for OSELTAMIVIR?
Summary for OSELTAMIVIR
| US Patents: | 0 |
| Applicants: | 29 |
| NDAs: | 36 |
| Drug Prices: | Drug price information for OSELTAMIVIR |
| Drug Sales Revenues: | Drug sales revenues for OSELTAMIVIR |
| DailyMed Link: | OSELTAMIVIR at DailyMed |
US Patents and Regulatory Information for OSELTAMIVIR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Strides Pharma | OSELTAMIVIR PHOSPHATE | oseltamivir phosphate | FOR SUSPENSION;ORAL | 211894-001 | Jan 13, 2022 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Rising | OSELTAMIVIR PHOSPHATE | oseltamivir phosphate | CAPSULE;ORAL | 210157-003 | Jan 21, 2021 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Macleods Pharms Ltd | OSELTAMIVIR PHOSPHATE | oseltamivir phosphate | CAPSULE;ORAL | 207211-003 | Sep 14, 2017 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Sunshine | OSELTAMIVIR PHOSPHATE | oseltamivir phosphate | CAPSULE;ORAL | 212739-002 | Mar 4, 2020 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Ajanta Pharma Ltd | OSELTAMIVIR PHOSPHATE | oseltamivir phosphate | FOR SUSPENSION;ORAL | 212784-001 | May 27, 2020 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
